TTNP Fundamental Analysis - TITAN PHARMACEUTICALS INC

Fundamental Rating

We assign a fundamental rating of 2 out of 10 to TTNP. TTNP was compared to 195 industry peers in the Pharmaceuticals industry. TTNP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TTNP does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

TTNP had negative earnings in the past year.

In the past year TTNP has reported a negative cash flow from operations.

In the past 5 years TTNP always reported negative net income.

In the past 5 years TTNP always reported negative operating cash flow.

1.2 Ratios

TTNP has a worse Return On Assets (-161.00%) than 86.15% of its industry peers.

TTNP has a Return On Equity of -192.87%. This is in the lower half of the industry: TTNP underperforms 67.18% of its industry peers.

		Industry Rank	Sector Rank
ROA	-161%
ROE	-192.87%
ROIC	N/A

ROA(3y)-160.51%

ROA(5y)-163.38%

ROE(3y)-341.83%

ROE(5y)-342.56%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TTNP so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

TTNP does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, TTNP has more shares outstanding

Compared to 5 years ago, TTNP has more shares outstanding

There is no outstanding debt for TTNP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

TTNP has an Altman-Z score of -188.52. This is a bad value and indicates that TTNP is not financially healthy and even has some risk of bankruptcy.

The Altman-Z score of TTNP (-188.52) is worse than 95.90% of its industry peers.

TTNP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-188.52

ROIC/WACCN/A

WACC9.9%

2.3 Liquidity

A Current Ratio of 6.05 indicates that TTNP has no problem at all paying its short term obligations.

TTNP has a Current ratio of 6.05. This is in the better half of the industry: TTNP outperforms 77.44% of its industry peers.

A Quick Ratio of 6.05 indicates that TTNP has no problem at all paying its short term obligations.

TTNP's Quick ratio of 6.05 is fine compared to the rest of the industry. TTNP outperforms 77.44% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	6.05
Quick Ratio	6.05

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 29.34% over the past year.

TTNP shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.

EPS 1Y (TTM)29.34%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%66.89%

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TTNP. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

TTNP does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

TITAN PHARMACEUTICALS INC

NASDAQ:TTNP (6/6/2025, 5:50:15 PM)

After market: 4.56 -0.09 (-1.94%)

4.65

-0.26 (-5.32%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)05-13 2025-05-13

Earnings (Next)08-13 2025-08-13

Inst Owners1.49%

Inst Owner Change410.69%

Ins Owners43.56%

Ins Owner Change0%

Market Cap4.23M

Analysts43.33

Price TargetN/A

Short Float %1.56%

Short Ratio0.22

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	N/A
P/FCF	N/A
P/OCF	N/A
P/B	1.73
P/tB	1.73
EV/EBITDA	N/A

EPS(TTM)-5.23

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)-4.26

FCFYN/A

OCF(TTM)-4.26

OCFYN/A

SpS0

BVpS2.68

TBVpS2.68

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-161%
ROE	-192.87%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-160.51%

ROA(5y)-163.38%

ROE(3y)-341.83%

ROE(5y)-342.56%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	6.05
Quick Ratio	6.05
Altman-Z	-188.52

F-Score3

WACC9.9%

ROIC/WACCN/A

Cap/Depr(3y)N/A

Cap/Depr(5y)N/A

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)29.34%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%66.89%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-100%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y37.38%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y45.31%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y45.29%

OCF growth 3YN/A

OCF growth 5YN/A

TITAN PHARMACEUTICALS INC (TTNP) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens